GlassScriptPhysician profile
James P Thore
NPI 1417340423
$1,003.95
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2023: $181 · 2024: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $519.46 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbott Laboratories | $93.09 | 2023 | Octrode |
| Depuy Synthes Sales INC. | $71.98 | 2023-2024 | Vivigen Mis Delivery System, Conduit, Viper |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.99 | 2021 | |
| Baxter Healthcare | $32.34 | 2024 | Floseal |
| Si-Bone, INC. | $31.14 | 2024 | |
| Janssen Pharmaceuticals, INC | $30.89 | 2021 | |
| Allergan, INC. | $29.25 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.71 | 2021 | |
| Pfizer INC. | $25.43 | 2021 | |
| Gilead Sciences, INC. | $24.81 | 2021 | |
| Cerapedics INC. | $21.50 | 2023 | I-Factor Peptide Enhanced Bone Graft |
| Novo Nordisk INC | $18.02 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.44 | 2021 | |
| Bioventus LLC | $14.58 | 2023 | Bonescalpel |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $13.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Thore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.